Table 2:
Active Studies of PET/MRI for Breast Cancer
| NCT# | Title | Aim | # Patients |
|---|---|---|---|
| Glucose Metabolism Imaging with 18F-Fluorodeoxyglucose (FDG) | |||
| 03510988 | Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women with Newly Diagnosed Breast Cancer | To determine any incremental added benefit to breast MRI specificity by the addition of concurrent hybrid breast PET | 147 |
| 01672021 | Initial Assessment of FDG-PET/MRI in Determining the Extent of Systemic Disease in Breast Cancer Patients | To assess the ability of FDG-PET/MR imaging to detect systemic disease in breast cancer patients as compared with conventional FDG-PET/CT | 80 |
| 04829643 | Targeting the Future of Axillary Staging in Early Breast Cancer: A Comparative Study: Sentinel Node Biopsy vs PET/MRI | To compare the staging power between sentinel node biopsy and PET/MRI in detecting axillary lymph node macrometastases | 247 |
| 04826211 | Targeting the Future of Axillary Staging in Node Positive Breast Cancer Patients Receiving Primary Systemic Therapy. A Comparative Study Between Sentinel Node Biopsy vs PET/MRI | To compare the staging power between sentinel node biopsy or lymphadenectomy vs PET/MRI | 110 |
| 03374826 | Non-invasive Axillary Lymph Node Staging in Breast Cancer With PET-MRI | To determine the accuracy of dedicated axillary hybrid PET/MRI to exclude axillary lymph node metastases in clinically node negative patients | 125 |
| 04273555 | Monitoring Early Response to Targeted Therapy in Stage IV Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients with Advanced PET/MRI | To evaluate PET/MRI for monitoring treatment response | 20 |
| Hypoxia Imaging with 18F-Fluoromisonidazole (FMISO) | |||
| 04332588 | Monitoring HER2+ Breast Cancer Neoadjuvant Treatment with Advanced PET/MRI | To evaluate PET/MRI with FMISO for monitoring and predicting the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer | 25 |
| 04861077 | Monitoring Breast Cancer Immunotherapy Treatment with Advanced PET/MRI: A Pilot Study | To investigate the utility of FMISO PET/MRI in patients with triple negative stage II-IV breast cancer to monitor and predict the effect of immunotherapy | 20 |
| Estrogen Receptor Imaging with 18F-Fluoroestradiol (FES) | |||
| 03703492 | PET/MRI of Estrogen Receptor Expression in Non-Invasive Breast Cancer | To compare quantitative FES uptake of biopsy-proven ductal carcinoma in situ measured using PET/MRI with ER protein levels determined by immunohistochemistry | 34 |
| Progesterone Receptor Imaging with 18F-Fluorofuranylnorprogesterone (FFNP) | |||
| 03212170 | FFNP PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer | To test the accuracy of PET/MRI imaging with FFNP for measuring progesterone receptor expression in patients with invasive breast cancer | 28 |
| HER2 Imaging with 89Zr-Df-Trastuzumab | |||
| 03321045 | PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness | To measure the diagnostic quality (with standardized uptake values) of PET/MRI imaging with 89Zr-Df-Trastuzumab in patients with newly diagnosed breast cancer | 10 |
| Gastrin-Releasing Peptide Receptor (GRPR) Imaging with Gallium 68-labeled GRPR Antagonist BAY86–7548 | |||
| 03831711 | A Pilot Study of 68Ga-RM2 PET/MRI in the Evaluation of Patients with Estrogen Receptor-Positive Breast Cancer | To evaluate the feasibility of 68Ga-RM2 PET/MRI for identification of estrogen receptor positive primary breast cancer and metastases | 20 |
Registered on ClinicalTrials.gov, June 202